Vyne Therapeutics
在场
Vyne Therapeutics 是一家在股票代码 VYNE (US) 下上市的公司。
高管
查看带有其 11 名主要高管的组织结构图
Vyne Therapeutics 搜索最多的简介
- David Domzalski, Chief Executive Officer and Director
- Steve Basta, Director
- Elisabeth Sandoval, Director
高管在Vyne Therapeutics变化
- Subhashis Banerjee已作为Senior Vice President of Clinical Development加入公司 (新闻发布的2024七月10号).
创建提醒
跟踪 Vyne Therapeutics 的高管变动
生物技术
Vyne Therapeutics 拥有 2,334 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Sai Life Sciences 刚刚宣布为 650 筹款数百万美元。 (公布2024十二月18号).
- Cala Health 刚刚宣布为 50 筹款数百万美元。 (公布2024十二月16号).
- Angitia Biopharmaceuticals 刚刚宣布为 120 筹款数百万美元。 (公布2024十二月16号).
生物技术 行业的其他推荐联系人
消息
Vyne Therapeutics 的最新新闻稿
- VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update – VYNE Therapeutics
- VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor – VYNE Therapeutics
- VYNE Therapeutics to Participate in September Investor Conferences – VYNE Therapeutics
- VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development – VYNE Therapeutics
- In the News – VYNE Therapeutics
- VYNE Reports First Quarter 2024 Financial Results and Provides Business Update
- VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor – VYNE Therapeutics
- VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting – VYNE Therapeutics
- VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference – VYNE Therapeutics
- VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
- View more press releases Close
通过电子邮件
